Unveiling 5 Analyst Insights On Editas Medicine
Throughout the last three months, 5 analysts have evaluated Editas Medicine (NASDAQ:EDIT), offering a diverse set of opinions…
The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts
Across the recent three months, 4 analysts have shared their insights on Editas Medicine (NASDAQ:EDIT), expressing a variety…
Editas Medicine To Present Clinical Data From The RUBY And EdiTHAL Trials Of Reni-cel At The EHA 2024 Congress In June
Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and
Editas Medicine Highlights 2024 Anticipated Milestones And Strategic Priorities At The J.P. Morgan Healthcare Conference
Anticipated 2024 milestones include: present reni-cel clinical data updates mid-year and year-end, initiate the RUBY clinical trial adolescent cohort, establish in vivo preclinical proof-of-concept for an undisclosed
The Latest Analyst Ratings for Editas Medicine
Within the last quarter, Editas Medicine (NASDAQ:EDIT) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Editas Medicine Announces New EDIT-301 Safety And Efficacy Data In 17 Patients, Presented Today At The American Society Of Hematology Annual Meeting And In A Company-Sponsored Webinar
All RUBY patients with ≥5 months follow-up have achieved a normal hemoglobin level and a fetal hemoglobin level of >40%All patients treated in the RUBY trial are free of vaso-occlusive events post-EDIT-301
Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday’s Mid-Day Session
Gainers
Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740.
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session.
Earnings Scheduled For November 3, 2023
Companies Reporting Before The Bell
• Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million.
A Preview Of Editas Medicine’s Earnings
Editas Medicine (NASDAQ:EDIT) is set to give its latest quarterly earnings report on Friday, 2023-11-03. Here’s what investors…